Boosting bone marrow after transplant or other treatment for aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a new treatment to help restore blood cell production in people with aplastic anemia whose bone marrow isn't working well after a stem cell transplant or other therapies. The goal is to improve blood counts and reduce the need for transfusions or support medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your bone marrow function is poor after a stem cell transplant, or your aplastic anemia has come back or not responded to standard treatments.
- You must be able to take care of yourself and be up and about more than 50% of the day (ECOG score 0 or 1).
- Your doctor thinks you are likely to live at least 6 more months.
- You cannot have severe graft-versus-host disease (GVHD) or an active cancer needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests new medications for people who develop severe acute graft-versus-host disease (aGVHD) within 100 days after their first stem cell transplant. The goal is to find safer, more effective ways to control aGVHD and improve recovery.
This trial tests whether two drugs—ruxolitinib (a JAK inhibitor) and azacitidine (a low-dose chemotherapy)—can help prevent acute myeloid leukemia from coming back after you receive a stem cell transplant from an unrelated donor. The transplant uses a gentler conditioning approach to reduce side effects while fighting the cancer.
This study tests a new first-line therapy for patients who develop grade II acute graft-versus-host disease (GVHD) after their first stem cell transplant. It aims to find better ways to treat this complication.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
Hear when a new Poor Graft Function trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.